Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
Authors
Keywords
-
Journal
Cancers
Volume 5, Issue 4, Pages 919-942
Publisher
MDPI AG
Online
2013-07-26
DOI
10.3390/cancers5030919
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Investigation of the HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC): Clinical data from the phase I/II SHELTER study.
- (2017) Michael Bitzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Recent Advancements of Bortezomib in Acute Lymphocytic Leukemia Treatment
- (2013) Xiao-Li Du et al. ACTA HAEMATOLOGICA
- The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review
- (2013) Limor Amit et al. PLoS One
- Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors
- (2012) John H. Strickler et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors
- (2012) Suzanne F. Jones et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors
- (2012) U. Banerji et al. CLINICAL CANCER RESEARCH
- An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors
- (2012) Nicola Tinari et al. CURRENT CANCER DRUG TARGETS
- The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment
- (2012) M. Stiborova et al. CURRENT MEDICINAL CHEMISTRY
- A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study
- (2012) Don S. Dizon et al. GYNECOLOGIC ONCOLOGY
- Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer
- (2012) Don S. Dizon et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group
- (2012) Winnie Yeo et al. JOURNAL OF CLINICAL ONCOLOGY
- The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice
- (2012) Takuya Kitamura et al. JOURNAL OF HEPATOLOGY
- Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies
- (2011) W. P. Yong et al. ANNALS OF ONCOLOGY
- Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo
- (2011) B. Ramaswamy et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours
- (2011) A R A Razak et al. BRITISH JOURNAL OF CANCER
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
- (2011) P N Munster et al. BRITISH JOURNAL OF CANCER
- Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor
- (2011) Paul Hamberg et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer
- (2011) M. G. Fakih et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase II Trial of Panobinostat, a Histone Deacetylase Inhibitor, in the Treatment of Patients with Refractory Metastatic Renal Cell Carcinoma
- (2011) John D. Hainsworth et al. CANCER INVESTIGATION
- New drug therapies in peripheral T-cell lymphoma
- (2011) Rebecca A Howman et al. Expert Review of Anticancer Therapy
- Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors
- (2011) Sachi Morita et al. INVESTIGATIONAL NEW DRUGS
- Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination
- (2011) Michael Millward et al. INVESTIGATIONAL NEW DRUGS
- Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors
- (2011) Claudia P. Miller et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Colorectal Cancer Epigenetics: Complex Simplicity
- (2011) Manon van Engeland et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors
- (2011) Giuseppe Giaccone et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma
- (2011) J. Drappatz et al. JOURNAL OF NEURO-ONCOLOGY
- Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study
- (2011) B. B. Friday et al. NEURO-ONCOLOGY
- Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma
- (2011) Prakash Chinnaiyan et al. NEURO-ONCOLOGY
- Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors
- (2011) M. M. Singh et al. NEURO-ONCOLOGY
- A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours
- (2010) U Lassen et al. BRITISH JOURNAL OF CANCER
- The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells
- (2010) Sonja Mandl-Weber et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer
- (2010) Dana Rathkopf et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy
- (2010) Peter M. Wilson et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells
- (2010) Cao Yang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Autophagic Survival in Resistance to Histone Deacetylase Inhibitors: Novel Strategies to Treat Malignant Peripheral Nerve Sheath Tumors
- (2010) G. Lopez et al. CANCER RESEARCH
- A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Two Schedules of Vorinostat in Combination with 5-Fluorouracil and Leucovorin in Patients with Refractory Solid Tumors
- (2010) M. G. Fakih et al. CLINICAL CANCER RESEARCH
- HDACs and HDAC inhibitors in colon cancer
- (2010) John M. Mariadason Epigenetics
- The role of histone deacetylases in prostate cancer
- (2010) Ata Abbas et al. Epigenetics
- Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours
- (2010) Helen J. Mackay et al. EUROPEAN JOURNAL OF CANCER
- Inside HDAC with HDAC inhibitors
- (2010) Philippe Bertrand EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors
- (2010) Mark Andrew Dickson et al. INVESTIGATIONAL NEW DRUGS
- Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies
- (2010) Bryan J. Schneider et al. INVESTIGATIONAL NEW DRUGS
- Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
- (2010) Mario Federico et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
- (2010) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor
- (2010) David Moffat et al. JOURNAL OF MEDICINAL CHEMISTRY
- Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer: A Wisconsin Oncology Network Phase II Study
- (2010) Anne M. Traynor et al. Journal of Thoracic Oncology
- Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma
- (2010) Suresh S. Ramalingam et al. Journal of Thoracic Oncology
- SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer
- (2010) V. Novotny-Diermayr et al. MOLECULAR CANCER THERAPEUTICS
- Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
- (2009) P N Munster et al. BRITISH JOURNAL OF CANCER
- Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)
- (2009) Deborah Bradley et al. CANCER
- Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma
- (2009) G. Lopez et al. CLINICAL CANCER RESEARCH
- A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer
- (2009) M. G. Fakih et al. CLINICAL CANCER RESEARCH
- Rational Combinations Using HDAC Inhibitors
- (2009) M. Bots et al. CLINICAL CANCER RESEARCH
- JNJ-26481585, a Novel "Second-Generation" Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity
- (2009) J. Arts et al. CLINICAL CANCER RESEARCH
- Clinical Studies of Histone Deacetylase Inhibitors
- (2009) H. M. Prince et al. CLINICAL CANCER RESEARCH
- Modifying chromatin architecture during the response to DNA breakage
- (2009) Ashok R. Venkitaraman CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY
- An operational definition of epigenetics
- (2009) S. L. Berger et al. GENES & DEVELOPMENT
- Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells
- (2009) William Fazzone et al. INTERNATIONAL JOURNAL OF CANCER
- Histone deacetylase inhibitors: Potential in cancer therapy
- (2009) P.A. Marks et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Histone Deacetylase Inhibitors in Cancer Therapy
- (2009) Andrew A. Lane et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
- (2009) Evanthia Galanis et al. JOURNAL OF CLINICAL ONCOLOGY
- Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer
- (2009) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
- (2008) Nagma Khan et al. BIOCHEMICAL JOURNAL
- Synthesis and structure–activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group
- (2008) Po C. Chen et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells
- (2008) Annie Hurtubise et al. Cancer Cell International
- Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma
- (2008) V. R. Fantin et al. CANCER RESEARCH
- Histone Deacetylase Inhibition and Blockade of the Glycolytic Pathway Synergistically Induce Glioblastoma Cell Death
- (2008) V. Egler et al. CLINICAL CANCER RESEARCH
- A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors
- (2008) N. L. Steele et al. CLINICAL CANCER RESEARCH
- Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors
- (2008) J. S. de Bono et al. CLINICAL CANCER RESEARCH
- A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
- (2008) T. H. Luu et al. CLINICAL CANCER RESEARCH
- A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
- (2008) Susan C. Modesitt et al. GYNECOLOGIC ONCOLOGY
- Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer
- (2008) Johan Vansteenkiste et al. INVESTIGATIONAL NEW DRUGS
- Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid Carcinoma
- (2008) Jennifer A. Woyach et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors
- (2008) Martin Haefner et al. WORLD JOURNAL OF GASTROENTEROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started